Westudied the feasibility and adverse effects of transpulmonary contrast echocardiography using sonicated albumin in 6 dogs. Left heart contrast was observed by two-dimensional echocardiography, monitoring left ventricular pressure, its first derivative (dP/dt) and arterial oxygen saturation. The left heart was adequately opacified in 48 of 55 injections of various intravenous doses of sonicated albumin. Left ventricular myocardial opacification was faintly observed in only 1 injection. After injections of a large dose (0.5 ml/kg), left ventricular systolic pressure decreased, maximal positive dP/dt decreased and negative dP/dt increased, slightly.
Introduction
Left heart contrast echocardiography has been performed by injecting contrast agents directly into the aortic root (1, 2) , the left ventricle (3, 4) or the coronary artery (2, (5) (6) (7) (8) . Although this technique has been helpful to identify abnormal cardiac structure (1 , 3) , determine valvular regurgitation (4) , demonstrate left-to-right shunts (4, 9) and evaluate myocardial perfusion (2, (5) (6) (7) (8) , the insertion of arterial catheters was required. Recently, several investigators have reported left heart contrast echocardiography following intrapulmonary, right atrial or peripheral venous injection of contrast agents capable of transpulmonary passage (10) (11) (12) (13) (14) (15) (16) . It is anticipated that if a large dose of a transpulmonary contrast agent is injected intravenously, enough microbubbles would reach the left heart cavity to opacify the left ventricular myocardium. Before applying this technique to patients, however, possible complications attributable to a large dose administration should be recognized.
Amongtranspulmonary contrast agents, sonicated albumin has been proposed as a moreideal contrast agent because its microbubbles are relatively small and cause neither a hyperemic response nor significant hemodynamic effects even with intracoronary use (17, 18). Although custom-made sonicated albumin microspheres (Albunex, Molecular Biosystems Inc., San Diego, CA., U.S.A.) have been recently developed, further clinical trials are required before its approval for human use ( 10, 1 1) . Therefore, in the present study, we made albumin microbubbles by sonication and investigated the feasibility of transpulmonary contrast echocardiography and the adverse effects of this contrast agent.
Material and Methods

Contrast agent preparation
Fifteen ml of 5% human serum albumin solution in a 20 ml plastic syringe was sonicated with a commercially available sonicating system (Sonifier 250, Branson Inc., Danbery, CT., U.S.A.) using a 3 mmtitanium-tipped horn at 20 kHz at a power output of 20 W for 30 seconds (19). The tip of the horn was placedjust below the surface of the solution and was fixed at that position throughout the sonication. Immediately after sonication, the solution was drained from the bottom of the syringe into a separate syringe and used for injection after discarding the first Transpulmonary Contrast Echo by Albumin 
Experimental protocol
Various doses of sonicated albumin were randomly bolus injected into the femoral vein and followed immediately by a 5 ml saline flush. The doses were 0.025 (16 trials), 0.05 (18 trials), 0.25 (8 trials) and 0.5 ml/kg (13 trials). After each injection, there was a lapse of at least 7 minutes before the next injection. Two-dimensionaland M-mode echocardiogramswere obtained by a commercially available 5 MHzphased-array transducer with an echocardiograph system (Toshiba SSH-60A, Toshiba Medical, Tokyo, Japan) during each injection and were recorded on a half-inch VHSvideotape recorder (Model 6400, Victor, Tokyo, Japan). To avoid echo attenuation in the left heart due to strong contrast echo in the right heart, four chamber views were obtained by placing the transducer directly on the left ventricle. Since a dog has a vertical heart, it was difficult to put the transducer just on the apex in our model and thus, a distorted four chamber view was obtained ( Fig. 1 ). Gray scale, depth, power, and reject or dynamic range controls were adjusted to provide the best ultrasound image during the baseline recordings and were held constant for the experiment in each dog. M-modeechocardiograms of the left heart were also recorded on a strip chartrecorder at a paper speed of25 mm/sec.
A standard lead II electrocardiogram, left ventricular pressure, dP/dt and arterial oxygen saturation were recorded continuously with a multichannel recorder (Nihon Denki San-ei, Tokyo, Japan) during each injection. All of the recordings and measurements were performed without turning off the respirator. The animals used in this study were handled in accordance with the guidelines of the committee on animal studies at the National Cardiovascular Center. Analysis of contrast intensity To quantify the contrast echo intensity, weused a commercially available high-speed image processing system capable of digitizing echocardiographic fields in real time (Model LA-555, PIAS Co, Tokyo, Japan) using apersonal computer (Model PC-9801, NEC Co, Tokyo, Japan). This system was used to convert each two-dimensional echocardiographic image in the video tape to a 5 12x5 12 pixel image with 256 gray levels/pixel and to quantify the intensity of echocardiographic signals in the regions of interest that were outlined by the operator. We positioned the regions of interest in the center of the left ventricle and the interventricular septum excluding the endocardium and epicardium. The regions of interest were circles with a diameter of 8 mmand 5 mm, respectively. When outlining the regions in the ventricular cavity, great care was taken to avoid cardiac structures such as myocardial walls, mitral and tricuspid chordae and valve leaflets irrespective of the respiratory change of cardiac position. The gray level within the region of interest before injection wassubtracted from the values after injection.
The subtracted values (contrast echo intensities) were printed with the frame numbers. The system used also printed the plot of contrast echo intensities in relation to time from the first analyzed end-diastole. In the analysis of the ventricular cavity opacification, peak contrast intensities and durations of opacification showing more than 5 units of contrast intensity were analyzed. 
Results
Left heart opacification
Weintravenously injected sonicated albumin 55 times in total. In 48 trials, the left heart cavity was adequately opacified after several beats of right heart opacification ( Fig. 1) . From the analysis of the time-contrast intensity curve, the peak contrast intensity tended to be higher and the duration of opacification tended to be longer as the injected dose increased (Figs. 2, 3 ). Left ventricular myocardial opacification was faintly visualized in only 1 of 13 injections at a large dose of sonicated albumin (0.5 ml/kg). Time-contrast echo intensity curves in the regions of the left ventricular cavity and the interventricular septum of that case shows myocardial opacification following left heart cavity opacification (Fig. 4) . Contrast enhancement of the left ventricular myocardium was not seen with the other trials.
Hemodynamic data and oxygen saturation (Table 1 , Fig. 5 ) Hemodynamicparameters did not show significant changes after intravenous injection of 0.025 and 0.05 ml/kg sonicated albumin. With the 0.25 ml/kg injection, only the left ventricular systolic pressure decreased slightly. In contrast, after injections at a large dose of 0.5 ml/kg, left ventricular systolic pressure decreased and the amplitude of maximal positive and negative dP/dt decreased, although the changes were transient (Fig. 5) . Left ventricular end-diastolic pressure did not show significant changes with all injections. Arterial oxygen saturation tended to decrease after intravenous sonicated albumin. The decrease was most remarkable with a large dose of0.5 ml/kg (mean 3%). As shown in Figure 5 , arterial oxygen saturation decreased significantly for about 30 seconds after injection and it required about 1 to 2 minutes to recover completely.
Discussion
Left heart cavity opacification
Keller and colleagues have demonstrated that sonicated albumin was an echogenic agent capable of transpulmonary passage (12) . It was shown that 3 to 5 ml of intravenous imaging by transpulmonary contrast agents. In the current study, myocardial opacification was faintly visualized in 1 injection with a large dose, which was confirmed using a highspeed image processing system. However, the myocardial opacification was not reproducible in the other 1 1 injections with the same dose. Therefore, it is considered that myocardial perfusion imaging with a peripheral injection of sonicated albumin must be difficult in the present experimental system. Ten Cate et al reported that they observed left ventricular myocardial opacification in 24 of 152 studies (16%) of intrapulmonary injections of 8 ml of sonicated (Schering Japan Co., Osaka, Japan) or sorbitol 70% (13). On the other hand, Smith and coworkers reported that they did not observe the left ventricular myocardial opacification after intravenous injection of 2 ml of the saccharide lung-crossing agent SHU-508 (Schering Japan Co., Osaka, Japan) (16). Recently, Adverse effects of intravenous sonicated albumin To date, most reports have not demonstrated any serious adverse effect of intravenous or intrapulmonary injection of contrast agents (1 1-13, 15, 16 ). Some investigators assessed the effect of intravenous contrast agents on arterial blood gas by blood sampling (12, 16 ). However, they might not detect an acute or temporary change in arterial blood gas induced by contrast agents because they did not monitor the change continuously. To continuously measure arterial oxygensaturation, weused an oximeter catheter and studied the effects of various doses of sonicated albumin on arterial blood gas. We found a transient but significant decrease in arterial oxygen saturation after a moderate to large dose of sonicated albumin injection, which soon recovered. There have been a few reports that demonstrated hemodynamicdeterioration attributable to intravenous injection of contrast agents (14, 26). We, unlike others (ll-13, 15, 16), have found transient but significant deteriorations in hemodynamic parameters after a large dose injection, which also soon recovered without special treatment. The cause of these adverse effects are unknown. Although we preliminarily checked the effect of a large dose of intravenous non-sonicated albumin (0.5 ml/kg) on hemodynamics and arterial oxygensaturation, no significant adverse effects were observed. Therefore, adverse effects described here may not be due to a large dose of albumin itself. The median size of the albumin microbubble used in the present study was as small as 5 \xm, but larger microbubbles were contained in the injected solution. They might cause temporary obstruction of pulmonary capillary flow and might lead to deterioration of arterial oxygen saturation. A recent study has shown that intravenous injection of Albunex (microbubble size, 3.9±0.3 to 5.8±0.1 jLim), even with a larger dose than the present study's, did not deteriorate arterial oxygen tension (27). It also has been demonstrated that Albunex did not induce any changes in the left atrial, left ventricular and pulmonary artery pressures after injection to the right atrium (1 1, 27). These studies support our hypothesis that the microbubble size is an important factor that influences gas exchange in the lung and hemodynamics. Whether these changes in hemodynamics and gas exchange in the lung were based on organ ischemia or not remain unclear. More studies are needed concerning the mechanismof these adverse effects.
Clinical implications
Wehave demonstrated the efficacy and limitations of intravenous sonicated albumin as a transpulmonary echo-contrast agent. Intravenous sonicated albumin can adequately opacify the left heart cavity even in a small dose of 0.025 ml/kg without adverse effects. Theoretically, myocardial perfusion imaging with peripheral venous injection of contrast agents may be accomplished if adequate contrast effect is achieved in the left heart cavity. However, we showedthat when a large dose of sonicated albumin was injected, hemodynamicparameters and arterial oxygen saturation might deteriorate. Although these changes soon recovered without special treatment, the present results might provide caution for the clinical application of a large dose of intravenous sonicated albumin to patients who have impaired systolic and/or arterial gas exchange function. However, the present study does not degrade the usefulness of transpulmonary contrast echocardiography. It is important that a small dose of sonicated albumin could enhance the left heart cavity without any adverse effects. Moreover, the adverse effects induced by a large dose of sonicated albumin will be mitigated by the use ofnontoxic, stable and smaller size contrast agents such as Albunex (1 1, 27). Transpulmonary contrast echocardiography is an exciting technique for the future. Further developmentof contrast agents and easy analysis methods will be needed before this technique can be widely used clinically.
